Anticancer Research

DecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma

Retrieved on: 
Thursday, October 5, 2023

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a new study demonstrating DecisionDx®-Melanoma outperforms a nomogram developed at the Memorial Sloan Kettering Cancer Center (MSKCC) in predicting the risk of sentinel lymph node (SLN) positivity in patients with cutaneous melanoma (CM).

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a new study demonstrating DecisionDx®-Melanoma outperforms a nomogram developed at the Memorial Sloan Kettering Cancer Center (MSKCC) in predicting the risk of sentinel lymph node (SLN) positivity in patients with cutaneous melanoma (CM).
  • The MSKCC nomogram, which uses logistic regression and only clinical and pathologic factors to predict a patient’s SLN positivity risk.
  • Patients from previously published multicenter cohorts with T1-T2 tumors who had undergone the SLNB procedure (n=465) were analyzed using both DecisionDx-Melanoma and the MSKCC nomogram.
  • DecisionDx-Melanoma also demonstrated better accuracy in predicting SLN positivity, including higher sensitivity (95% vs. 81%) and negative predictive value (97% vs. 90%) than the MSKCC nomogram.

AntiCancer’s PDOX Mouse Model Has Demonstrated High Clinical Concordance Which Will Enable Precise Individualized Chemotherapy of Cancer Patients

Retrieved on: 
Monday, October 2, 2023

AntiCancer Inc. of San Diego has announced its PDOX mouse model of human cancer patients has demonstrated high concordance of chemotherapy in the mouse and patient.

Key Points: 
  • AntiCancer Inc. of San Diego has announced its PDOX mouse model of human cancer patients has demonstrated high concordance of chemotherapy in the mouse and patient.
  • “This new result means AntiCancer has made the first steps for precise, individualized cancer chemotherapy,” said Qinghong Han, Senior Scientist at AntiCancer Inc. “The PDOX mouse model has the patient’s tumor implanted in the same organ in the mouse as it was in the patient enabling very accurate prediction of chemotherapy outcome for the patient,” said Dr. Han.
  • “AntiCancer’s technique of patient-tumor establishment in mice is close to 100%, making the PDOX model available potentially to all patients,” technique-inventor and AntiCancer-Japan General Manager Chihiro Hozumi said.
  • The latest paper on clinical concordance of the PDOX model is published in the October 2023 issue of Anticancer Research.

The MZB Foundation for Cancer Research Publishes in PLOS ONE Journal

Retrieved on: 
Monday, October 31, 2022

Treatments predictably improve survival 2-3-fold and add years of survival for young, old, and risk-averse patients with or without resistant tumors.

Key Points: 
  • Treatments predictably improve survival 2-3-fold and add years of survival for young, old, and risk-averse patients with or without resistant tumors.
  • Bruckner earlier found that some drugs are more effective when combined at low concentrations compared to the same drugs combined at high concentrations.
  • Similar benefit for patients with advanced stomach, small bowel, and gynecological cancers, is reviewed in Anticancer Research, Bruckner and others 2016 and 2018.
  • The algorithm selects platforms to expand the MZB Foundation for Cancer Research's priorities for drug development, safety, and drug interactions that have contributed to five widely used treatments.

Propanc Biopharma Presents 100 Years of Clinical Evidence for “Novel” Enzyme Therapeutic Approach to Treat Cancer

Retrieved on: 
Thursday, May 26, 2022

Propanc Biopharma, Inc. (OTCQB: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that 100 years of clinical evidence supporting the use of proenzymes as a new therapeutic approach to treat cancer can be considered compelling.

Key Points: 
  • Propanc Biopharma, Inc. (OTCQB: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that 100 years of clinical evidence supporting the use of proenzymes as a new therapeutic approach to treat cancer can be considered compelling.
  • After injections of commercially available pancreatic enzyme trypsin, the tumor in a treated mouse was much smaller than that in an untreated control.
  • Over several years, a number of physicians in the UK and US injected enzyme preparations with some remarkable success stories.
  • Over the years, there have been further clinical cases investigated into the use of enzymes as a way to treat cancer.

North America Breast Reconstruction Market Forecast to 2028 : Inframammary Segment Set for Largest Share of Technology in the North America Breast Reconstruction Market During 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 7, 2021

The "North America Breast Reconstruction Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology, Type; Placement, Procedure" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Breast Reconstruction Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology, Type; Placement, Procedure" report has been added to ResearchAndMarkets.com's offering.
  • The North American breast reconstruction market is expected to reach US$ 482.1 million by 2028 from US$ 312.2 million in 2021.
  • The report provides trends prevailing in the North America breast reconstruction market along with the drivers and restraints pertaining to the market growth.
  • In 2020, the inframammary by technology segment accounted for the largest share of the market.